

# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -02

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1<sup>st</sup> Lane Ambawadi,  
Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: [investor.relations@kashyaptele-medicines.com](mailto:investor.relations@kashyaptele-medicines.com),

Website: [www.kashyaptele-medicines.com](http://www.kashyaptele-medicines.com)

Date: 30<sup>th</sup> October, 2020

To,  
BSE Limited  
Listing Department  
Phiroz Jeejeebhoy Tower,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai-400001

Scrip Code – 531960

Sub.: Submission of Unaudited Financial Results of the Company and Limited Review Report  
for the second quarter and half year ended 30<sup>th</sup> September, 2020

Dear Sir/Madam,

With reference to above, we are pleased to submit herewith, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Unaudited Financial Results of the Company for the second quarter and half year ended 30<sup>th</sup> September, 2020, prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (IND-AS), as reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on 30<sup>th</sup> October, 2020.

Also please find enclosed herewith the Limited Review Report of the said Unaudited Financial Results of the Company for the second quarter and half year ended 30<sup>th</sup> September, 2020 as received from the Auditors of the Company.

Further, pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the said result will be duly published in the required newspaper in due course of time and will be uploaded on the website of the Company.

Kindly take the above disclosures on your record as compliance with Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take note of the same.

Thanking you.

Yours faithfully,

FOR, KASHYAP TELE-MEDICINES LIMITED

  
PRERNA KAKKAR  
COMPANY SECRETARY



Encl: As above

# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -02

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE SECOND QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020

(As per Schedule III Companies Act, 2013 and IND-AS)


(Rs In Lacs Except EPS)

S.No.	Particulars	Quarter Ended (Standalone)			Half Year Ended		Year Ended
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from operations	4.75	5.24	5.24	9.99	9.89	20.08
II	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
III	<b>Total Revenue ( I + II )</b>	<b>4.75</b>	<b>5.24</b>	<b>5.24</b>	<b>9.99</b>	<b>9.89</b>	<b>20.08</b>
IV	<b>Expenses</b>						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(d) Employee benefits expense	2.53	1.41	2.51	3.94	4.99	9.08
	(e) Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00	0.00
	(g) Other expenses	2.14	2.12	2.26	4.26	3.64	9.53
	<b>Total expenses</b>	<b>4.67</b>	<b>3.53</b>	<b>4.77</b>	<b>8.20</b>	<b>8.63</b>	<b>18.61</b>
V	<b>Profit before exceptional and extraordinary items and tax (III-IV)</b>	<b>0.09</b>	<b>1.71</b>	<b>0.47</b>	<b>1.80</b>	<b>1.26</b>	<b>1.47</b>
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit before extraordinary items and tax (V - VI)</b>	<b>0.09</b>	<b>1.71</b>	<b>0.47</b>	<b>1.80</b>	<b>1.26</b>	<b>1.47</b>
VIII	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Profit/(Loss) Before Tax ( VII- VIII)</b>	<b>0.09</b>	<b>1.71</b>	<b>0.47</b>	<b>1.80</b>	<b>1.26</b>	<b>1.47</b>
X	Tax Expense :-						
	(a) Current Tax	0.02	0.39	0.13	0.41	0.33	0.13
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total Tax Expense</b>	<b>0.02</b>	<b>0.39</b>	<b>0.13</b>	<b>0.41</b>	<b>0.33</b>	<b>0.13</b>
XI	<b>Profit / (Loss) for the period from continuing operations (IX - X)</b>	<b>0.07</b>	<b>1.32</b>	<b>0.34</b>	<b>1.39</b>	<b>0.93</b>	<b>1.34</b>
XII	Profit/(Loss) from Discontinuing Operations	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Tax expense of Discontinuing Operations	0.00	0.00	0.00	0.00	0.00	0.00
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00	0.00
XV	<b>Profit / (Loss) for the period (XI + XIV)</b>	<b>0.07</b>	<b>1.32</b>	<b>0.34</b>	<b>1.39</b>	<b>0.93</b>	<b>1.34</b>
XVI	Share of Profit / (Loss) of Associates	0.00	0.00	0.00	0.00	0.00	0.00
XVII	Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	<b>Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates*</b>	<b>0.07</b>	<b>1.32</b>	<b>0.34</b>	<b>1.39</b>	<b>0.93</b>	<b>1.34</b>
XIX	<b>Other Comprehensive Income</b>						
	A. Items that will be/will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total comprehensive income for the period (XVIII+XIX)</b>	<b>0.07</b>	<b>1.32</b>	<b>0.34</b>	<b>1.39</b>	<b>0.93</b>	<b>1.34</b>
XX	<b>Paid-up Equity Share Capital (Face Value of Rs. 1/- each)</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>
XXI	<b>Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>						<b>(238.89)</b>
XXII	<b>Earnings per equity Share: (not annualised)</b>	<b>0.000</b>	<b>0.003</b>	<b>0.001</b>	<b>0.003</b>	<b>0.002</b>	<b>0.003</b>
	(a) Basic and Diluted EPS						

### Notes:

- The above Unaudited Financial Results of the Company for the second quarter and half year ended 30th September, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors in the Meeting held on 30th October, 2020.
- The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Ind As') from 1st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and discloses the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India ( Listing Obligations and Disclosure Requirements) Regulation, 2015 ( as amended).
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results for the second quarter and half year ended 30th September, 2020 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
- A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).
- Estimates of uncertainties relating to the global pandemic from COVID-19:  
The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of receivables, revenues and intangible assets. In developing the assumptions relating to the possible future uncertainty in the global economic condition because of this pandemic, the Company as at the date of approval of these financial statement has used internal and external sources of informations, economic forecasts and consensus estimates from market sources on the expected future performance of the Company. The Company has performed sensitivity analysis on the estimates expects the carrying amount of these assets will be recovered.
- Pursuant to compliance of SEBI notification No. SEBI/LAD-NRO/GN/2018/10 dated 9th May, 2018, the Company has also submitted as part of its standalone financial results for the half year ended 30th September, 2020, by way of a note, a statement of cash flows for the half-year ended 30th September, 2020 as enclosed in the said notes to the Financial Statements
- The Company is engaged in single segment therefore has only one reportable segment in accordance with Ind AS 108 'operating segments'.
- Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.

Place : Ahmedabad  
Date : 30th October, 2020



For, Kashyap Tele - Medicines Limited

  
 Amit Agrawal  
 Managing Director  
 DIN: 00169061



# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -02  
 Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006  
 Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com  
 Website: www.kashyaptele-medicines.com


## UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES

Rs. In Lakhs

	As at 30/09/2020 (UnAudited)	As at 31/03/2020 (Audited)
<b>ASSETS</b>		
<b>I Non-Current Assets</b>		
(a) Property, Plant and Equipment	-	-
(b) Capital work in progress	-	-
(c) Financial Assets	-	-
(i) Investments	21	21
(ii) Other Financial Assets	0.34	0.34
(d) Other Non-Current Assets	194.40	191.69
	<b>215.75</b>	<b>213.03</b>
<b>II Current Assets</b>		
(a) Inventories	-	-
(b) Financial Assets	-	-
(i) Trade Receivables	22.24	12.99
(ii) Cash and Cash Equivalents	0.44	10.77
(iii) Investments	-	-
(iv) Loans	-	-
(c) Other Current Assets	3.39	2.85
(d) Accrued Interest - FDR	-	-
	<b>26.07</b>	<b>26.61</b>
<b>TOTAL ASSETS</b>	<b>241.82</b>	<b>239.64</b>
<b>EQUITY AND LIABILITIES</b>		
<b>I Equity</b>		
(a) Share Capital	477.22	477.22
(b) Other Equity	(237.51)	(238.89)
	<b>239.71</b>	<b>238.33</b>
<b>II Non Current Liabilities</b>		
(a) Long term borrowings	-	-
(b) Deferred tax liabilities (net)	-	-
(c) Other long term liabilities	-	-
<b>III Current Liabilities</b>		
(a) Financial liabilities		
(i) Short term borrowings	-	-
(ii) Trade Payables	-	-
Total Outstanding dues of micro enterprises and small enterprises	-	-
Total Outstanding dues of creditors other than micro enterprises and small enterprises	0.37	-
(iii) Other Financial liabilities	0.98	0.97
(b) Other Current Liabilities	0.00	-
(c) Short-Term Provisions	-	-
(d) Income tax liabilities	0.74	0.34
	<b>2.10</b>	<b>1.31</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>241.82</b>	<b>239.64</b>

Place : Ahmedabad

Date : 30th October, 2020



For, Kashyap Tele - Medicines Limited



Amit Agrawal  
 Managing Director  
 DIN: 00169061

**KASHYAP TELE-MEDICINES LIMITED**

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -02

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

**CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2020**

		(Rs. In Lakhs)	
	Particulars	Year ended 30/09/2020	Year ended 31/03/2020
<b>A</b>	<b>Cash flow from operating activities:</b>		
	Profit before tax	1.79	1.46
	Adjustments		
	Operating profit before working capital changes	1.79	1.46
	Adjustments for changes in working capital :		
	Change in trade receivables	(9.25)	(0.59)
	Change in other receivables	(3.25)	(2.10)
	Change in Current Liabilities & other payables	0.38	(2.03)
	Cash flow from/ (used in) operations	(10.33)	(3.25)
	Income taxes paid	0.00	0.59
	Net cash flow from/(used in) operating activities	(10.33)	(3.85)
<b>B</b>	<b>Cash flow from investing activities:</b>		
	Net cash (used in)/flow from investing activities		
<b>C</b>	<b>Cash flow from financing activities:</b>		
	Net cash (used in)/flow from financing activities:		
<b>D</b>	<b>Net increase in cash and cash equivalents</b>	<b>(10.33)</b>	<b>(3.85)</b>
	Cash and cash equivalents at the beginning of the year (refer note 19)	10.77	14.62
	Cash and cash equivalents at the end of the year	0.44	10.77
<b>E</b>	<b>Cash and cash equivalents comprises of:</b>		
	Balances with banks		
	on current accounts	0.12	10.45
	Cash on hand	0.32	0.32
		0.44	10.77

Place : Ahmedabad

Date : 30th October, 2020



For, Kashyap Tele - Medicines Limited



Amit Agrawal  
Managing Director  
DIN: 00169061



# SAREMAL & CO

## Chartered Accountants

CA Saremal Shah (Bcom, FCA); CA Pravin Lavana (Bcom, LLB, FCA)

**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE QUARTERLY UNAUDITED FINANCIAL RESULTS FOR THE SECOND QUARTER AND HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER, 2020 OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED**


To  
The Board of Directors,  
**KASHYAP TELE-MEDICINES LIMITED**  
**AHMEDABAD**

1. We have reviewed the accompanying statement of Un-audited Financial Statements of **M/S KASHYAP TELE-MEDICINES LIMITED** (the Company) for the secondquarter and half year ended 30<sup>th</sup>September, 2020being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations,2015as amended (the 'Listing Regulations'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29<sup>th</sup> March, 2019 and SEBI Circular No. CIR/CFD/CMD1/80/2019 dated 19<sup>th</sup> July, 2019.This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Statement on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our Conclusion is not modified in respect of this matter.



FOR, SAREMAL & CO.  
Chartered Accountants

  
**PRAVIN LAVANA**  
(Partner)  
MEMBERSHIP NO.:037180  
FIRM REGISTRATION NO.: 109281W  
UDIN: 20037180AAAED2809

Ahmedabad , October 30, 2020